Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.

NCT03390595 is registered in ClinicalTrials.gov with Associació per a la Recerca Oncologica, Spain as lead sponsor.

NCT NCT03390595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03390595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.
Lead sponsor
Associació per a la Recerca Oncologica, Spain
Phase
Phase 2
Overall status
Completed
Start date
May 17, 2018
Completion date
August 31, 2022
Enrollment
85 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cancer